Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
Gynecologic Pathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
Int J Cancer. 2019 Aug 15;145(4):882-893. doi: 10.1002/ijc.32139. Epub 2019 Feb 12.
Many genomic assays that assess recurrence risk in early breast cancer (EBC) are prognostic, but they differ in risk group stratification, which can affect clinical utility. Prospective outcomes of >60 K patients treated based on the 21-gene assay results have shown that chemotherapy may be safely omitted in EBC patents with low Recurrence Score (RS) results (RS < 18). Because of its extensive validation and wide clinical use, the RS assay is a common comparator in head-to-head studies with other assays. Published/presented studies of the RS assay performed on the same tumor samples with Breast Cancer Index (BCI), EndoPredict (EP) or EP+ clinical features (EPclin), MammaPrint (MMP) and/or Prosigna (ROR) assays were reviewed. Study findings were summarized descriptively.
许多评估早期乳腺癌（EBC）复发风险的基因组检测是预后性的，但它们在风险分组分层方面存在差异，这可能会影响临床实用性。基于 21 基因检测结果治疗的 >60000 名患者的前瞻性结果表明，对于复发评分（RS）较低（RS<18）的 EBC 患者，化疗可能可以安全省略。由于其广泛的验证和广泛的临床应用，RS 检测在与其他检测的头对头研究中是一种常见的比较器。对使用乳腺癌指数（BCI）、EndoPredict（EP）或 EP+临床特征（EPclin）、MammaPrint（MMP）和/或 Prosigna（ROR）检测在同一肿瘤样本上进行的 RS 检测的已发表/已提交研究进行了回顾。总结了研究结果的描述性。
